These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31371179)

  • 21. Impact of pharmacist counseling to enhance the accessibility of naloxone nasal spray to patients in a community pharmacy setting.
    Napoli K; Grant M; Remines J; Nadpara P; Goode JR
    J Am Pharm Assoc (2003); 2021; 61(4S):S127-S134. PubMed ID: 33441280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
    Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
    J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
    Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
    Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addressing the opioid epidemic through community pharmacy engagement: Study protocol for a randomized controlled trial.
    Gamble A; Mashburn T; Kennelty KA; Look KA; Westrick SC; Evon DM; Tudor G; Carpenter DM
    Contemp Clin Trials; 2022 Oct; 121():106920. PubMed ID: 36096283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. State legal innovations to encourage naloxone dispensing.
    Davis C; Carr D
    J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies.
    Spivey CA; Wilder A; Chisholm-Burns MA; Stallworth S; Wheeler J
    J Am Pharm Assoc (2003); 2020; 60(5):694-701.e1. PubMed ID: 32146134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
    Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE
    J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder.
    Zalmai R; Hill LG; Loera LJ; Mosgrove Q; Brown C
    J Am Pharm Assoc (2003); 2023; 63(5):1558-1565.e4. PubMed ID: 37331654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal.
    Nielsen S; Menon N; Larney S; Farrell M; Degenhardt L
    Addiction; 2016 Dec; 111(12):2177-2186. PubMed ID: 27367125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
    Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
    J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacists' naloxone offering and dispensing practices.
    Thakur T; Kile M; Chewning B
    J Opioid Manag; 2022; 18(2):133-141. PubMed ID: 35476882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is known about community pharmacy supply of naloxone? A scoping review.
    Nielsen S; Van Hout MC
    Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature.
    Muzyk A; Smothers ZPW; Collins K; MacEachern M; Wu LT
    Subst Abus; 2019; 40(4):476-483. PubMed ID: 31418645
    [No Abstract]   [Full Text] [Related]  

  • 36. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
    Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
    Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A content review of online naloxone Continuing Education courses for pharmacists in states with standing orders.
    Carpenter DM; Roberts CA; Westrick SC; Ferreri SP; Kennelty KA; Look KA; Abraham O; Wilson C
    Res Social Adm Pharm; 2018 Oct; 14(10):968-978. PubMed ID: 29239777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose.
    Skoy E; Werremeyer A; Steig J; Eukel H; Frenzel O; Strand M
    Subst Abus; 2021; 42(4):672-677. PubMed ID: 33044896
    [No Abstract]   [Full Text] [Related]  

  • 39. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
    Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
    J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study.
    Pollini RA; Slocum S; Ozga J; Joyce R; Xuan Z; Green TC; Walley AY
    J Am Pharm Assoc (2003); 2022; 62(1):157-166. PubMed ID: 34511372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.